Trial Profile

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alogliptin (Primary) ; Alogliptin/pioglitazone (Primary) ; Pioglitazone
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics; Registrational
Sponsors Takeda

12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
26 Apr 2012 New source identified and integrated (EudraCT2007-000486-38: European Clinical Trials Database).
12 Jan 2012 Results published in the Diabetologia.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com